5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients

Официальное название

Immunomodulatory and Therapeutic Efficacy of 5-methyltetrahydrofolate Supplementation on Autoimmune Status in Type 1 Diabetes Mellitus

Обзор

This study aims to evaluate the improvement of autoimmune status in patients with Type 1 Diabetes (T1D) through supplementation with 5-Methyltetrahydrofolate, and to explore the safety and efficacy of this treatment. The research seeks to provide new methods for the treatment of T1D and offer innovative ideas for enhancing the quality of life of T1D patients.

Вмешательства

• Препарат active folate
  Daily oral intake of active folate 800ug combined with basic diabetic treatment
• Препарат Placebo
  take oral placebo daily combined with basic diabetic treatment

Первичные конечные точки

• Islet β cell function [Срок оценки: From enrollment to 24 weeks of treatment]

Вторичные конечные точки (6)

• HbA1c [Срок оценки: From enrollment to 24 weeks of treatment]
• lymphocyte subsets [Срок оценки: From enrollment to 24 weeks of treatment]
• islet autoantibodies [Срок оценки: From enrollment to 24 weeks of treatment]
• insulin dosage [Срок оценки: 24 weeks of treatment]
• cytokines [Срок оценки: From enrollment to 24 weeks of treatment]
• CRP [Срок оценки: From enrollment to 24 weeks of treatment]

Критерии участия

Критерии включения

• Diagnosed with T1D based on the World Health Organization (WHO) classification criteria for disease diagnosis.
• Aged 13-65 years, regardless of gender.
• Duration of T1D ≤ 5 years.
• Retained residual islet function, defined as fasting C-peptide > 0.1 nmol/L \[0.30 ng/mL\] or postprandial 2-hour C-peptide > 0.2 nmol/L \[0.60 ng/mL\].
• Determined by the investigator to be capable and willing to: perform self-monitoring of blood glucose (SMBG); complete patient logs as required; receive diabetes education; and comply with the study treatment and visit schedule as per the protocol.

6\) Signed informed consent form, with parental/guardian consent and signature required for pediatric/adolescent participants.

Критерии исключения

• Serum 5-methyltetrahydrofolate or folate levels exceeding the upper limit of the normal reference range.
• Currently experiencing acute metabolic disorders, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state.
• Women who are breastfeeding, pregnant, or planning to become pregnant during the trial.
• Received immunosuppressive or immunomodulatory therapy within the past year.
• Comorbid with other autoimmune diseases, such as systemic lupus erythematosus.
• Severe liver, kidney, gastrointestinal, hematologic, cerebral, or circulatory system diseases.
• Psychiatric or neurological disorders leading to non-cooperation, non-adherence to medication, substance abuse, or other related issues.
• Malignancy.
• Recent surgery or significant stress.
• Known hypersensitivity or allergic reaction to 5-methyltetrahydrofolate or its excipients.
• Investigator's judgment of significant evidence of severe, active, or uncontrolled endocrine or autoimmune abnormalities.
• Currently participating in another clinical trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

• Vukotic R, Di Donato R, Roncarati G, Simoni P, Renzulli M, Gitto S, Schepis F, Villa E, Berzigotti A, Bosch J, Andreone P. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. J Hepatol. 2023 Oct;79(4):977-988. doi: 10.1016/j.jhep.2023.06.017. Epub 2023 Jul 22. PMID 37482222
• Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998 Jan 27;97(3):237-41. doi: 10.1161/01.cir.97.3.237. PMID 9462523
• Giammarco S, Chiusolo P, Maggi R, Rossi M, Minnella G, Metafuni E, D'Alo F, Sica S. MTHFR polymorphisms and vitamin B12 deficiency: correlation between mthfr polymorphisms and clinical and laboratory findings. Ann Hematol. 2024 Oct;103(10):3973-3977. doi: 10.1007/s00277-024-05937-z. Epub 2024 Aug 28. PMID 39196375

Идентификаторы

NCT: NCT06930144 · CZYZ-5MTHF-2025-IIT

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗